Related Experiment Videos
Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma
Cheng-Jueng Chen1, Satoru Kyo, Yao-Chi Liu
1Division of General Surgery, Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan, China.
World Journal of Gastroenterology
|March 3, 2004
Summary
c-Myc does not significantly regulate human telomerase reverse transcriptase (hTERT) in hepatocellular carcinoma. Further research is needed to understand hTERT gene regulation in this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Telomerase activation is crucial for cancer cell immortality.
- The human telomerase reverse transcriptase (hTERT) gene is a key determinant of telomerase activity.
- c-Myc binding sites in the hTERT promoter regulate its transcription, but its role in hepatocellular carcinoma is unclear.
Purpose of the Study:
- To investigate the role of c-Myc in the transcriptional regulation of the human telomerase reverse transcriptase (hTERT) gene in human hepatocellular carcinoma.
- To determine the relationship between c-Myc oncoprotein expression and hTERT mRNA levels in hepatocellular carcinoma tissues.
Main Methods:
- Quantification of hTERT mRNA and c-Myc oncoprotein expression in 57 hepatocellular carcinoma patient samples using in situ hybridization and immunohistochemistry.
- Luciferase reporter assays to evaluate hTERT promoter activity and the effect of c-Myc binding site mutations in a hepatocellular carcinoma cell line.
Main Results:
- A correlation between hTERT mRNA and c-Myc protein expression was observed in 52% of cases.
- However, a significant portion of tumors showed hTERT expression independent of c-Myc levels.
- Luciferase assays indicated that c-Myc binding sites within the hTERT promoter region did not significantly impact its transcriptional activity.
Conclusions:
- c-Myc does not appear to be a major regulator of hTERT gene expression in human hepatocellular carcinoma.
- Additional regulatory mechanisms, including other transcription factors and epigenetic modifications, likely contribute to hTERT regulation in this cancer.